Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years
Back

A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years

Completed

Open to: ALL

Age: 12.0 - N/A

Dundee London Bristol Lincoln London London London Newcastle Truro

Medical Conditions

Epilepsy

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this study is to evaluate the safety and tolerability of Fycompa (Perampanel) as an add-on therapy in epilepsy patients aged greater than or equal to 12 years.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jun 2014 Jan 2018

Publications

"Maguire M. Response to \"Perampanel and pregnancy: Could experience be a gloomy lantern that does not even illuminate its bearer?\". Epilepsy Behav. 2022 Apr;129:108654. doi: 10.1016/j.yebeh.2022.108654. Epub 2022 Mar 16. No abstract available."; "35305920"; "Maguire M, Ben-Menachem E, Patten A, Malhotra M, Ngo LY. A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy. Epilepsy Behav. 2022 Jan;126:108483. doi: 10.1016/j.yebeh.2021.108483. Epub 2021 Dec 23."; "34953337"

OBSERVATIONAL

Intervention Type : DRUG
Intervention Description : Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment

Intervention Arm Group : Perampanel;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Ninewells Hospital
    Dundee
    DD1 9SY
  • Great Ormond Street Hospital
    London
  • Eisai Site# 1607
    Bristol
  • Eisai Site# 1611
    Lincoln
  • Eisai Site# 1604
    London
  • Eisai Site# 1608
    London
  • Eisai Site# 1609
    London
  • Eisai Site# 1612
    Newcastle
  • Eisai Site# 1606
    Truro


The study is sponsored by Eisai Inc.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT02033902
Last updated 06 September 2018

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top